Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same author

Radioligand Therapy for Prostate Cancer - A Clinical Consultation Guide.

European urology focus·2026
Same author

Prognostic Value of Restaging [<sup>18</sup>F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Perioperative ctDNA as a prognostic biomarker in endometrial cancer - the CODEC study.

Translational oncology·2026
Same author

Prostate Cancer Working Group 4 Recap.

European urology focus·2026

Related Experiment Video

Updated: Dec 24, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K

Mechanistic Insights for Optimizing PSMA Radioligand Therapy.

Aravind S Ravi Kumar1,2, Michael S Hofman1,2

  • 1Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. aravind.ravikumar@petermac.org michael.hofman@petermac.org.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 8, 2020
PubMed
Summary

Prostate cancer treatment using PSMA radioligand therapy shows promise. Visualizing the target with theranostics helps understand treatment variability and improve patient selection for better results.

More Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.4K
Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

1.8K

Related Experiment Videos

Last Updated: Dec 24, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.4K
Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

1.8K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiochemistry

Background:

  • Prostate cancer remains a significant health concern.
  • PSMA radioligand therapy is an emerging treatment modality.
  • Variability in clinical outcomes is linked to PSMA expression heterogeneity.

Purpose of the Study:

  • To explore the role of PSMA expression heterogeneity in prostate cancer treatment.
  • To discuss the application of theranostics for visualizing PSMA targets.
  • To identify strategies for optimizing patient selection and therapeutic efficacy.

Main Methods:

  • Review of current literature on PSMA radioligand therapy.
  • Analysis of theranostic approaches for PSMA visualization.
  • Discussion of clinical strategies for patient stratification.

Main Results:

  • PSMA expression heterogeneity significantly impacts treatment response.
  • Theranostics offer mechanistic insights into treatment efficacy.
  • Improved patient selection can enhance therapeutic outcomes.

Conclusions:

  • PSMA radioligand therapy holds significant potential for prostate cancer.
  • Theranostic visualization is key to understanding and overcoming treatment variability.
  • Clinical strategies are needed to optimize patient selection and maximize treatment benefits.